RD50 values of transfectants
| DC-3F/G338A339 | DC-3F/A338 | DC-3F/P339 | DC-3F/A338P339 | |
|---|---|---|---|---|
| CsA | ||||
| ActD | 109 ± 56 (1) | 285 ± 9 (2.6) | 2012 ± 294 (18.5) | 782 ± 369 (7.2) |
| COLC | 101 ± 24 (1) | 225 ± 10 (2.2) | 1657 ± 70 (16.4) | 1015 ± 20 (10.0) |
| VCR | 64 ± 8 (1) | 118 ± 9 (1.8) | 1876 ± 104 (29.3) | 1300 ± 264 (20.3) |
| DAUN | 166 ± 60 (1) | 153 ± 6 (0.9) | 2154 ± 234 (13.0) | 843 ± 551 (5.1) |
| VRP | ||||
| ActD | 499 ± 59 (1) | 561 ± 72 (1.1) | 791 ± 39 (1.6) | 731 ± 334 (1.5) |
| COLC | 425 ± 78 (1) | 1628 ± 268 (3.8) | 2205 ± 294 (5.2) | 3441 ± 1608 (8.1) |
| VCR | 403 ± 20 (1) | 395 ± 34 (1.0) | 686 ± 48 (1.7) | 437 ± 133 (0.9) |
| DAUN | 368 ± 22 (1) | 422 ± 9 (1.2) | 461 ± 14 (1.3) | 605 ± 267 (1.6) |
RD50 values (ng/ml) of the transfectants for CsA and VRP were determined by linear regression analysis of the resistance versus reversal agent dosage curves in Fig. 3. Values shown are the mean of multiple determinations (>3). Values in parentheeis are ratios of the RD50 values for each drug normalized to those of the wild-type.